Optimistic Buy Rating for Precision BioSciences Driven by Promising Safety Data and Potential Functional Cure for HBV

Analyst Soumit Roy from JonesTrading maintained a Buy rating on Precision BioSciences (DTIL – Research Report) and keeping the price target at $30.00.

Soumit Roy’s rating is based on the promising safety data presented by Precision BioSciences at the EASL 2025 conference. The data from the Phase 1 ELIMINATE-B trial showed that the PBGENE-HBV treatment for chronic HBV did not present any significant safety concerns at the low dose level, with only mild and transient adverse events reported. This positive safety profile is an encouraging sign for the potential of the treatment as it progresses to higher doses and additional administrations.
Furthermore, the ongoing research and future updates expected in 2025, including those at ASGCT and later in the year, are anticipated to provide more insights into the drug’s efficacy as a functional cure for chronic HBV. The potential for achieving a functional cure, characterized by non-detectable HBsAg and HBV DNA, remains a key focus. These factors contribute to the optimistic outlook and the Buy rating for Precision BioSciences’ stock.

According to TipRanks, Roy is an analyst with an average return of -25.5% and a 18.18% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Chimerix, and Oric Pharmaceuticals.

In another report released on May 5, H.C. Wainwright also maintained a Buy rating on the stock with a $60.00 price target.